Open Targets Director, Wellcome Trust Sanger Institute
Jeff Barrett is the Director of Open Targets, a public-private partnership between GSK, Biogen, the European Bioinformatics Institute and the Wellcome Trust Sanger Institute to analyse genome-scale human genetics data to change the earliest stage of making medicines: identifying and validating the right targets for new treatments. He is also a group leader at the Sanger Institute, where he uses next-generation sequencing in thousands of individuals to find variation associated with both rare and common human diseases. He first became interested in human genetics in Mark Daly's lab at the Whitehead Institute before moving to Oxford to undertake a D. Phil in statistical genetics with Lon Cardon & Peter Donnelly. Jeff was an analyst in the Wellcome Trust Case Control Consortium, and led early GWAS meta-analyses in inflammatory bowel disease and type 1 diabetes while a postdoc with David Clayton in Cambridge.